🦴
Our bone cancer program combines limb-salvage surgery innovation with targeted therapies for osteosarcoma, Ewing sarcoma, and chondrosarcoma.
Learn MoreWhole-genome sequencing to identify copy number alterations and chromothripsis events driving chemoresistance in osteosarcoma.
3D-printed custom prostheses and navigation-guided resection to maximise function after tumour removal.
Evaluating IGF-1R inhibitors and EZH2 inhibitors as novel therapeutic approaches in relapsed Ewing sarcoma.
NCT06234517
ActivePI: Dr. Mayilvahanan Bose
NCT06234518
RecruitingPI: Dr. Mayilvahanan Bose
Your support funds innovative limb-salvage surgery technologies and genomic research that give young bone cancer patients the best chance at a full, active life.
Donate Now
.png&w=96&q=75){kind=small}